Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor is a research paper published in Journal for ImmunoTherapy of Cancer (2021). On theSindex it has a DataRank of 0. It has been cited 99 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Providence Portland Medical Foundation
Grant: N/A
NIH/NCI
Grant: R21CA190790
National Institutes of Health
Grant: 1R21CA190790-01
Ipilimumab plus a galectin-3 inhibitor for metastatic melanoma
FWCI
4.55
Citation Percentile
1.0%
Influential Citations
2
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals